Personalised pharmacometabolomic optimisation of treatment for hypertension (HYPERMARKER)

高血压治疗的个性化药物代谢组学优化（HYPERMARKER）

• 批准号: 10066774
• 金额: $ 37.2万
• 依托单位: LONDON SCHOOL OF ECONOMICS & POL SCI
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10066774
• 关键词: Personalised; pharmacometabolomic; optimisation; treatment; hypertension

Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which continue to dominate as the leading cause of death and morbidity across the EU. It accounts for almost 10 percent of all healthcare-related costs. Systolic hypertension leads to a broad variety of diseases with an immense impact on both patients and healthcare systems. HYPERMARKER will unleash the potential of pharmacometabolomics to provide a ‘smart’ prescription of antihypertensive therapy. Well-phenotyped cohortsfrom eleven European countries will provide metabolomic profiles and blood samples for pharmacometabolomic assessments to identify predictors of treatment response in hypertension using advanced AI and deep learning methods. Prediction models for individual treatment responses to antihypertensive medication will be clinically validated and refined through an innovative RCT across 4 sites in Europe. The result is a clinical decision support tool that will give clinicians the ability to make an informed selection of whether the patient they are treating will best respond to the use of angiotensin inhibition, calcium antagonists, beta-blockers, or a range of other existing drugs with evidence-based for BP control. To ensure sustainability, the project will also develop a framework for the uptake of this tool in routine care for patients with hypertension across Europe and beyond. HYPERMARKER will be implemented by a group of world-class scientists and clinicians from a diversity of disciplines who have collaborated multiple times and have a track record of leading key national and EU-funded initiatives to deliver high-impact results.

高血压或高血压（BP）是一种严重的医学疾病，也是循环系统疾病的最大贡献者，循环系统疾病仍然是欧盟死亡和发病的主要原因。它占所有医疗保健相关费用的近10%。收缩性高血压导致各种疾病，对患者和医疗保健系统都有巨大影响。HYPERMARKER将释放药物代谢组学的潜力，为抗高血压治疗提供“智能”处方。来自11个欧洲国家的表型良好的队列将提供代谢组学特征和血液样本，用于药物代谢组学评估，以使用先进的AI和深度学习方法确定高血压治疗反应的预测因素。抗高血压药物个体治疗反应的预测模型将通过欧洲4家研究中心的创新RCT进行临床验证和完善。其结果是一个临床决策支持工具，将使临床医生能够做出明智的选择，他们正在治疗的患者是否将最好地响应使用血管紧张素抑制剂，钙拮抗剂，β-受体阻滞剂，或一系列其他现有的药物与证据为基础的血压控制。为了确保可持续性，该项目还将制定一个框架，用于在欧洲及其他地区的高血压患者的常规护理中使用该工具。HYPERMARKER将由一群来自不同学科的世界级科学家和临床医生实施，他们曾多次合作，并在国家和欧盟资助的主要举措中拥有领先的记录，以提供高影响力的结果。